Akintunde Olatokumbo Bello
CIK: 0002070709
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
XLO
Xilio Therapeutics, Inc.
Director
Discretionary Trading P&L
Holdings
About Bello Akintunde Olatokumbo
Bello Akintunde Olatokumbo (SEC CIK 0002070709) files insider reports with the SEC as Director of Xilio Therapeutics, Inc. (XLO).
Signal8 holds 3 ownership filings by Bello Akintunde Olatokumbo (1 Form 3, 2 Form 4), filed between Jun 12, 2025 and Jun 12, 2026. Those filings report 2 transactions, from Jun 10, 2025 to Jun 11, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Bello Akintunde Olatokumbo's filings is in WALTHAM, MA.
Recent filings by Bello Akintunde Olatokumbo
Other insiders filing for Xilio Therapeutics, Inc. (XLO)
- Houvras Yariv, CHIEF MEDICAL OFFICER
- Shannon James Samuel, Director
- Curran Daniel J., Director
- Xu Yuan, Director
- ROSS ROBERT W., Director
- Bonstein Sara, Director